Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?

TY - JOUR

T1 - Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?

AU - De Ruysscher, Dirk

AU - Remon, Jordi

AU - Hendriks, Lizza E L

N1 - Funding Information: Lizza Hendriks: research funding AstraZeneca (iinstitutino). Outside of current manuscript: research funding Roche Genentech , Boehringer Ingelheim (all institution, Takeda and Beigene under negotiation); advisory board: BMS , Eli Lilly , Roche Genentech , Pfizer , Takeda , MSD , Merck , Novartis , Boehringer Ingelheim , Amgen , Janssen (all institution, Roche one time self); speaker: MSD , Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech , Bayer , Lilly (institution); local PI of clinical trials: AstraZeneca , Novartis , BMS , MSD / Merck , GSK , Takeda , Blueprint Medicines, Roche Genentech , Janssen Pharmaceuticals , Mirati. Funding Information: Dirk De Ruysscher: Institutional research grants and support: Astra Zeneca, BMS, BeiGene, Olink, Philips. Advisory board (no personal fees): AstraZeneca, Philips.Lizza Hendriks: research funding AstraZeneca (iinstitutino). Outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim (all institution, Takeda and Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Merck, Novartis, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD/Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati.

PY - 2022/5

Y1 - 2022/5

U2 - 10.1016/j.ejca.2022.02.015

DO - 10.1016/j.ejca.2022.02.015

M3 - Editorial

C2 - 35307255

SN - 0959-8049

VL - 167

SP - 149

EP - 151

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -